Sunvozertinib Plus Anlotinib as 1L Treatment in EGFR-Sensitive Mutations Combined With Co-Mutations Advanced NSCLC
Conditions: Non-Small Cell Lung Cancer Interventions: Drug: sunvozertinib in combination with Anlotinib Sponsors: Hunan Province Tumor Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 5, 2024 Category: Research Source Type: clinical trials
Totally Robotic Versus Surgeon-Assisted Robotic Lung Resection For Early-Stage NSCLC: A RCT
Conditions: Lung Cancer Interventions: Device: Medtronic Signia Stapler; Device: Vessel Sealer Extend Energy Device and SureForm Stapler Sponsors: St. Joseph ' s Healthcare Hamilton Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 4, 2024 Category: Research Source Type: clinical trials
Mediastinal EBUS Cryobiopsy Study In Sweden
Conditions: Mediastinal Lymphadenopathy; Lung Cancer; Sarcoidosis; Lymphoma; Tuberculosis Interventions: Diagnostic Test: Mediastinal lymph nodes cryobiopsies Sponsors: Region Skane Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 4, 2024 Category: Research Source Type: clinical trials
Construction and Effect Evaluation of the Low Load Blood Flow Restriction Training Program for Lung Cancer Patients Complicated With Sarcopenia During Chemotherapy
Conditions: Sarcopenia; Lung Neoplasms Interventions: Behavioral: Low load blood flow restriction training; Behavioral: Progressive resistance training group Sponsors: Xin Wang Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 4, 2024 Category: Research Source Type: clinical trials
A Study to Compare the Efficacy, Safety, Pharmacokinetics, and Immunogenicity Between SB27 and Keytruda in Subjects With Metastatic Non-squamous Non-small Cell Lung Cancer
Conditions: Non-small Cell Lung Cancer Stage IV Interventions: Drug: SB27; Drug: Keytruda Sponsors: Samsung Bioepis Co., Ltd. Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 4, 2024 Category: Research Source Type: clinical trials
Totally Robotic Versus Surgeon-Assisted Robotic Lung Resection For Early-Stage NSCLC
Conditions: Lung Cancer Interventions: Device: Medtronic Signia Stapler; Device: Vessel Sealer Extend Energy Device and SureForm Stapler Sponsors: St. Joseph ' s Healthcare Hamilton Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 4, 2024 Category: Research Source Type: clinical trials
Merck Initiates Phase 3 Clinical Trial of MK-1084, an Investigational Oral KRAS G12C Inhibitor, in Combination with Keytruda (pembrolizumab) for First-Line Treatment of Certain Patients With Metastatic Non-Small Cell Lung Cancer
RAHWAY, N.J.--(BUSINESS WIRE) April 4, 2024 -- Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced it has initiated a Phase 3 clinical trial evaluating MK-1084, an investigational oral selective KRAS G12C... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - April 4, 2024 Category: Pharmaceuticals Source Type: clinical trials
A Study of MK-1084 Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant, Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004)
Conditions: Non-small Cell Lung Cancer Interventions: Drug: MK-1084; Other: Placebo; Biological: Pembrolizumab Sponsors: Merck Sharp& Dohme LLC Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 3, 2024 Category: Research Source Type: clinical trials
Volatolomic and Proteomic Profile for Early Diagnosis of Lung Cancer
Conditions: Lung Cancer; Non-small Cell Lung Cancer Stage I; Non-small Cell Lung Cancer Stage II; Lung Cancer Diagnosis Interventions: Other: Breath, urine and blood analysis Sponsors: European Institute of Oncology; University of Rome Tor Vergata Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 2, 2024 Category: Research Source Type: clinical trials
Risk Factors for AKI in Patients Undergoing VATS for Pulmonary Resection
Conditions: Acute Kidney Injury; Surgery; Lung Cancer Interventions: Other: Duration of Surgery; Other: Volume of Fluid in Surgery; Other: Blood Loss Sponsors: Atat ürk Chest Diseases and Chest Surgery Training and Research Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 2, 2024 Category: Research Source Type: clinical trials
The Optimal Number of Fiducial Marker for Stereotactic Body Radiotherapy
Conditions: Lung Cancer; Liver Cancer; Pancreatic Cancer; Renal Cell Carcinoma Interventions: Radiation: SBRT Sponsors: Peking University Third Hospital Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 2, 2024 Category: Research Source Type: clinical trials
Vebreltinib Plus PLB1004 in EGFR-mutated, Advanced NSCLC With MET Amplification or MET Overexpression Following EGFR-TKI
Conditions: Non-Small-Cell Lung Cancer Interventions: Drug: Vebreltinib; Drug: PLB1004 Sponsors: Avistone Biotechnology Co., Ltd. Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 2, 2024 Category: Research Source Type: clinical trials
Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer
Conditions: Non-small Cell Lung Cancer; Metastatic Non-Small Cell Lung Cancer; NSCLC; KRAS G12C; Metastatic Lung Cancer; Advanced Lung Carcinoma Interventions: Drug: BBO-8520; Drug: Pembrolizumab Sponsors: TheRas, Inc Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 2, 2024 Category: Research Source Type: clinical trials
Patient-Generated Health Data Collection During Chemoradiotherapy for Lung Cancer
Conditions: Thoracic Cancer Interventions: Radiation: Proton Beam Radiation with or without concurrent chemotherapy Sponsors: The New York Proton Center Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 2, 2024 Category: Research Source Type: clinical trials
Anlotinib Combined With Penpulimab as Front-line Treatment in Advanced Non-small Cell Lung Cancer
Conditions: Non-small Cell Lung Cancer Interventions: Drug: anlotinib combined with penpulimab Sponsors: The First Affiliated Hospital of Zhengzhou University Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 2, 2024 Category: Research Source Type: clinical trials
